Cipla

Accumulate Cipla; target of Rs 1,620: Deven Choksey

Deven Choksey recommended accumulate rating on Cipla with a target price of Rs 1,620 in its research report dated November 04, 2025.

Data Story: Cipla shone under Umang Vohra, task cut out for new CEO

Growth in the US business slowed in recent quarters

Accumulate Cipla; target of Rs 1675: Prabhudas Lilladher

Prabhudas Lilladher recommended accumulate rating on Cipla with a target price of Rs 1675 in its research report dated October 31, 2025.

Reduce Cipla; target of Rs 1580: Choice Equity Broking

Choice Equity Broking recommended reduce rating on Cipla with a target price of Rs 1580 in its research report dated October 31, 2025.

Umang Vohra, Cipla’s outgoing CEO says task achieved, ‘not retiring’ from sector

Vohra was the second executive roped in from outside Cipla’s promoter family to lead the drug maker. Under his watch, Cipla saw a sharp improvement in profitability, driven by strategic expansion in chronic therapies, operational efficiencies and global partnerships.

Cipla says Achin Gupta to replace Umang Vohra as Cipla MD, global CEO from April 1; shares fall 4%

This planned transition is in line with our succession process developed by the Board and Umang Vohra, says Cipla

Cipla shares fall 3% after Eli Lilly deal to market weight-loss drug in India: Here's what analysts say

Cipla share price: Analysts say that while the deal is a positive for the stock, it has already been priced in and investors are now resorting to profit booking.

Hold Cipla; target of Rs 1570: Deven Choksey

Deven Choksey recommended hold rating on Cipla with a target price of Rs 1570 in its research report dated September 08, 2025.

Buy Cipla; target of Rs 1754: Mirae Asset Sharekhan

Mirae Asset Sharekhan is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1754 in its research report dated September 02, 2025.

Trade Spotlight: How should you trade TCS, Exide Industries, Cipla, Max Financial Services, Hyundai Motor India, Nykaa, and others on August 26?

The market is likely to consolidate further until it decisively gets back above last Thursday's high. Below are some short-term trading ideas to consider.

Trade Spotlight: How should you trade DMart, Can Fin Homes, Radico Khaitan, Cipla, Dr Reddys Labs, Caplin Point, Afcons Infra, and others on August 22?

Overall, the trend remains favourable for bulls, despite the likelihood of intermittent consolidation. Below are some short-term trading ideas to consider.

Pharma stocks fall up to 2% as Trump threatens steep tariffs on drug imports

The US government has long sought to shift pharmaceutical manufacturing back to domestic soil, citing both economic and national security concerns.

Buy Cipla; target of Rs 1800: ICICI Securities

ICICI Securities is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1800 in its research report dated July 26, 2025.

Buy Cipla; target of Rs 1730: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1730 in its research report dated July 27, 2025.

Trade Spotlight: How should you trade TCS, Cipla, Torrent Pharma, NCC, Paytm, SBI Life Insurance, UPL, Syrma SGS Technology and others on July 29?

The market may continue to consolidate with a negative bias in the upcoming sessions. Below are some short-term trading ideas to consider.

Gainers & Losers: Top 10 stocks that moved the most on July 28

At close, the Sensex was down 572.07 points or 0.70 percent at 80,891.02, and the Nifty was down 156.10 points or 0.63 percent at 24,680.90. About 1207 shares advanced, 2766 shares declined, and 152 shares unchanged.

Cipla: Non-US markets to drive growth in the near term

Reduced contribution of Revlimid is likely to get offset by new products

Trade Spotlight: How should you trade Eternal, Cipla, Shyam Metalics, Torrent Pharma, Hubtown, Vimta Labs and others on July 28?

The market is expected to consolidate further as long as the frontline indices continue trading below their medium-term moving averages. Below are some short-term trading ideas to consider.

Gainers & Losers: Top 10 stocks that moved the most on July 25

About 1080 shares advanced, 2,771 shares declined, and 136 shares unchanged.

Cipla Q1 net profit beat estimates, jumps 10% to Rs 1,298 crore, revenue up 4%

Total revenue from operations rose 3.9 percent to Rs 6,957 crore in the period under review as compared with Rs 6,694 crore a year ago.

Cipla Q1FY26 preview: Margin pressure likely despite double-digit India growth

Cipla is expected to post muted profit growth for Q1FY26 despite steady revenue momentum, with US sales remaining flat and margin pressure weighing on the bottom line.